ES2151595T3 - Anticuerpos monoclonales que reconocen el receptor "tie" y sus aplicaciones. - Google Patents

Anticuerpos monoclonales que reconocen el receptor "tie" y sus aplicaciones.

Info

Publication number
ES2151595T3
ES2151595T3 ES95914366T ES95914366T ES2151595T3 ES 2151595 T3 ES2151595 T3 ES 2151595T3 ES 95914366 T ES95914366 T ES 95914366T ES 95914366 T ES95914366 T ES 95914366T ES 2151595 T3 ES2151595 T3 ES 2151595T3
Authority
ES
Spain
Prior art keywords
tie
receiver
applications
monoclonal antibodies
antibodies recognizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914366T
Other languages
English (en)
Inventor
Kari Alitalo
Marja-Terttu Matikainen
Paivi Karnani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MATIKAINEN MARJA TERTTU
Original Assignee
MATIKAINEN MARJA TERTTU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MATIKAINEN MARJA TERTTU filed Critical MATIKAINEN MARJA TERTTU
Application granted granted Critical
Publication of ES2151595T3 publication Critical patent/ES2151595T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN NUEVOS ANTICUERPOS, LOS CUALES SON REACTIVOS CON TIE, UN RECEPTOR DE QUINASA TIROSINA ENCONTRADO EN CELULAS ENDOTELIALES Y EN CIERTAS POBLACIONES DE CELULAS TUMORALES. SE DESCRIBEN LOS ANTICUERPOS MONOCLONALES ANTI-TIE Y SE SUMINISTRA EL ANTICUERPO MONOCLONAL 3C4C7G6, ASI COMO LA LINEA CELULAR HIBRIDOMA (DSM ACC2159) QUE LO PRODUCE. LOS ANTICUERPOS SON UTILES COMO HERRAMIENTAS DE DIAGNOSTICO PARA DETECTAR ENFERMEDADES NEOPLASTICAS PRODUCIENDO ANGIOGENESIS TUMORAL, CICATRIZACION DE HERIDAS Y UNA VARIEDAD DE ENFERMEDADES ASOCIADAS A LA ANGIOGENESIS Y PARA LA CREACION DE IMAGENES RADIOLOGICAS DE VASOS SANGUINEOS. ADEMAS, LOS ANTICUERPOS DESCUBIERTOS SON UTILES COMO AGENTES TERAPEUTICOS.
ES95914366T 1994-03-29 1995-03-29 Anticuerpos monoclonales que reconocen el receptor "tie" y sus aplicaciones. Expired - Lifetime ES2151595T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/220,240 US5955291A (en) 1992-01-09 1994-03-29 Antibodies recognizing tie receptor tyrosine kinase and uses thereof

Publications (1)

Publication Number Publication Date
ES2151595T3 true ES2151595T3 (es) 2001-01-01

Family

ID=22822698

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914366T Expired - Lifetime ES2151595T3 (es) 1994-03-29 1995-03-29 Anticuerpos monoclonales que reconocen el receptor "tie" y sus aplicaciones.

Country Status (13)

Country Link
US (1) US5955291A (es)
EP (1) EP0753015B1 (es)
JP (1) JP3683270B2 (es)
AT (1) ATE195533T1 (es)
AU (1) AU697185B2 (es)
CA (1) CA2185043C (es)
DE (1) DE69518406T2 (es)
DK (1) DK0753015T3 (es)
ES (1) ES2151595T3 (es)
MX (1) MX9604391A (es)
NO (1) NO319586B1 (es)
NZ (1) NZ283366A (es)
WO (1) WO1995026364A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
WO1996031598A1 (en) 1995-04-06 1996-10-10 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7063965B2 (en) 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6057435A (en) * 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
FR2783325A1 (fr) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Moyens pour le controle de la regulation negative d'une activation transmise par un rtk
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
DK1187918T4 (da) * 1999-06-07 2009-02-23 Immunex Corp TEK-antagonister
US6521424B2 (en) * 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
JP4981229B2 (ja) * 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
AU2001244509A1 (en) * 2000-03-30 2001-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treatment of conditions involving obstruction of blood flow
DK1790728T3 (da) 2000-11-06 2010-12-06 Cancer Rec Tech Ltd Billeddannelse, diagnose og behandling af sygdom
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
CA2485548A1 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
NZ537220A (en) * 2002-05-16 2008-06-30 Absorber Ab Method of isolating an endothelial cell and method of donor specific crossmatching
AU2003285500B8 (en) 2002-11-20 2011-02-03 Cancer Research Technology Limited Antibodies binding to human magic roundabout (MR), polypeptides and uses thereof for inhibition of angiogenesis
CA2522082A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
EP1479760A1 (de) * 2003-05-19 2004-11-24 ProBioGen AG Künstliches Immunorgan
AU2004266242A1 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP1709081B1 (en) * 2004-01-16 2011-04-06 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP1737949B1 (en) * 2004-03-09 2010-09-15 Absorber AB Endothelial progenitor cells and methods of use thereof
AU2005272848A1 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US9109446B1 (en) 2011-02-07 2015-08-18 Ameriband, Llc Continuously variable displacement engine
US10041405B1 (en) 2011-02-07 2018-08-07 Ameriband, Llc Continuously variable displacement engine
US9896933B1 (en) 2011-02-07 2018-02-20 Ameriband, Llc Continuously variable displacement engine
US9540932B1 (en) 2011-02-07 2017-01-10 Ameriband, Llc Continuously variable displacement engine
US9581057B1 (en) 2014-08-20 2017-02-28 Ameriband, Llc Valve actuator system capable of operating multiple valves with a single cam

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
WO1993014124A1 (en) * 1992-01-09 1993-07-22 Helsinki University Holding, Ltd. Tie, a novel endothelial cell receptor tyrosine kinase

Also Published As

Publication number Publication date
AU697185B2 (en) 1998-10-01
ATE195533T1 (de) 2000-09-15
CA2185043C (en) 2008-03-18
NZ283366A (en) 1998-04-27
DE69518406T2 (de) 2001-03-15
MX9604391A (es) 1997-07-31
NO964013D0 (no) 1996-09-24
AU2139295A (en) 1995-10-17
DE69518406D1 (de) 2000-09-21
JP3683270B2 (ja) 2005-08-17
DK0753015T3 (da) 2000-11-13
JPH09511141A (ja) 1997-11-11
NO964013L (no) 1996-09-24
EP0753015A1 (en) 1997-01-15
CA2185043A1 (en) 1995-10-05
EP0753015B1 (en) 2000-08-16
WO1995026364A1 (en) 1995-10-05
NO319586B1 (no) 2005-08-29
US5955291A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
ES2151595T3 (es) Anticuerpos monoclonales que reconocen el receptor "tie" y sus aplicaciones.
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
ATE110172T1 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
NZ333744A (en) Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg
EP0458079A3 (en) Ultrasonic contrast agent, its preparation and application as diagnostic or therapeutic
NO943625D0 (no) Monoklonale antistoffer mot interferonreseptoren med nöytraliserende aktivitet mot type-I-interferon
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
NO950037D0 (no) Fotoaktivering av proteiner for konjugasjonsformat
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
EP0674661A4 (en) TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS.
DE59608213D1 (de) Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
IL144265A0 (en) Use of antibodies for the vaccination against cancer
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
WO2001037874A3 (en) Treatment of psoriasis by using an antibody to tnf alpha
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
ES2149155T3 (es) Peptidos sinteticos que contienen secuencias de factor viia y su utilizacion.
ES2136085T3 (es) Fragmentos de hgpiib y su uso en procedimientos que permiten la determinacion in vitro de eventos tromboticos in vivo.
MXPA03009138A (es) Produccion de anticuerpos monoespecificos policlonales, contra variantes del receptor activador del plasminogeno de tipo uroquinasa (upar) del4, del5 y del4+5 y su uso para propositos de diagnostico y terapeutico.
Baughn et al. Evidence that autologous idiotypic regulation of anti-arginine-glycine-aspartic acid autoantibodies may influence development and progression of syphilitic lesions in infected rabbits
ATE204761T1 (de) Pharmazeutische antigen-/antikörperpräparation
DK182188A (da) Humant tumorassocieret antigen
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.
SE9202335D0 (sv) Fixeringsanordning

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 753015

Country of ref document: ES